Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Regeneron and CytomX Announce Strategic Research Collaboration for Cancer Treatment
Regeneron Pharmaceuticals and CytomX Therapeutics has announced a collaboration and licensing agreement to create conditionally-activated […]
Congruence Therapeutics Strengthens Leadership Team with Appointment of Dr. Sharath Hegde as Chief Scientific Officer
Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery […]
MilliporeSigma Invests $286 Million in U.S. Drug Safety Testing Capacity
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science […]
Lung Cancer Awareness Month Highlights Importance of Preventive Screenings
Advancements in staging and personalized treatments have helped improve lung cancer survival rates, but low […]
Navamedic ASA Acquires Innovative Antibiotics Product for Hospital Use in the Nordic Region
Navamedic has signed an agreement with its partner InfoRLife SA (subsidiary of ACS Dobfar S.p.A.) […]
Optibrium Appoints Ian Smith as Chief Technology Officer (CTO)
Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the […]
RedBrick AI Raises US$4.6M in Funding to Accelerate the Development of Healthcare AI
Health-tech AI platform RedBrick AI is today announcing a US$4.6M seed funding round to accelerate the […]
World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks
A potential new drug to improve the long-term outcomes for patients who suffer heart attacks […]
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease
AbbVie announced the European Commission (EC) has approved SKYRIZI (risankizumab, 600 mg intravenous [IV] induction and […]
FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes
The U.S. Food and Drug Administration (FDA) has approved Tzield (teplizumab-mzwv), an injection to delay […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more